Clinical trials: Alzheimer Dementia
Dementia, Alzheimer's Disease
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal…
- Trial name
- REMIND (NCT00283725)
- Testing
- No intervention
- Volunteers
- 573 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Moderate to Severe Alzheimer
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.
- Trial name
- CONTACT (NCT00954590)
- Testing
- Dimebon (latrepirdine)
- Where
- 2 sites in Chile, United Kingdom
- Volunteers
- 89 people
- Sponsor
- Medivation, Inc.
Postpartum Hypertension (PPHT)
Swiss Postpartum Hypertension Cohort
This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal…
- Trial name
- NCT04690660
- Testing
- Data collection for parameters of organ damage (cardiac and renal blood markers), Data collection for blood pressure (BP), Home-based blood pressure management (substudy)
- Where
- Switzerland
- Volunteers
- 480 people
- Sponsor
- University Hospital, Basel, Switzerland
Dementia, Dementia, Vascular
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Difficulty completing everyday tasks is a primary reason for the high cost of care, loss of caregiver paid hours, and general caregiver burden associated with dementia.
- Conditions
- Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed
- Trial name
- SmartPrompt (NCT04313582)
- Testing
- SmartPrompt smartphone application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Temple University
Alzheimer's Disease
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks.
- Trial name
- NCT00890890
- Testing
- Avagacestat
- Where
- 64 sites in United States, Canada and 4 more
- Volunteers
- 263 people
- Sponsor
- Bristol-Myers Squibb
Dementia Alzheimers
ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia
The proposed research project aims to answer the question "Are immersive technology systems effective in the management and treatment of patients with BPSD?".
- Trial name
- NCT05265182
- Testing
- virtual reality
- Where
- Philippines
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Augmented eXperience E-health Laboratory
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neurodegenerative Diseases, Memory Disturbances
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
Background: New research criteria for the diagnosis of Alzheimer's disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers.
- Trial name
- NCT01450891
- Where
- 4 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- Maastricht University Medical Center
Alzheimer Disease
ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD).
- Trial name
- NCT00063310
- Testing
- Leuprolide acetate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Voyager Pharmaceutical Corporation
Alzheimer Disease
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
The purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild Alzheimer…
- Trial name
- PLEODIAL-I (NCT02361424)
- Testing
- PXT00864
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Pharnext S.C.A.
Delirium, Neurocognitive Disorders
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older…
- Conditions
- Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- ENHANCE (NCT05929703)
- Testing
- HELP, FAM-HELP
- Where
- 7 sites in United States
- Volunteers
- 1,900 people
- Sponsor
- University of Michigan
Covid19, Death
COVID-19 Infections and Mortality in Long-term Care Facilities During the First Wave
The medical charts of all COVID-19 cases (n=1200) from 17 long-term care facilities in Montreal, Canada will be reviewed, to compare patients who survived to patients who did not survive.
- Conditions
- Covid19, Death, Infection Viral, Infections, Respiratory
- Trial name
- NCT04782427
- Testing
- COVID-19 infection
- Where
- Canada
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Alzheimer's Disease
Benefits of Exercise in Alzheimer's Disease
Exercise has been shown to be beneficial for the brain. The investigators would like to test this specifically for those diagnosed with Alzheimer's disease.
- Trial name
- NCT01935024
- Testing
- Personalized Exercise Regimen
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Alzheimer Disease, Aerobic Exercise
The Effects of Exercise Program in Alzheimer's Patients With Mild to Moderate Stage Alzheimer's Disease
The primary aim of this trial is to investigate the feasibility of an exercise program consisting of respiratory exercises, aerobic exercises and strengthening exercises in mild to moderate Alzheimer's disease.
- Conditions
- Alzheimer Disease, Aerobic Exercise, Breathing Exercise, Resistance Training
- Trial name
- NCT04021888
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Dokuz Eylul University
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
Virtual Reality Cognitive Therapy for Alzheimer's Disease
To evaluate the usability, feasibility, and acceptability of VRCT iteratively on 36 AD/ADRD individuals with mild to moderate CI.
- Trial name
- VRCT (NCT05788848)
- Testing
- VRCT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Claritytek, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Cognitive Impairment, Dementia
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by…
- Conditions
- Cognitive Impairment, Dementia, Alzheimer Disease, Delirium
- Trial name
- NCT05395559
- Where
- Netherlands
- Volunteers
- 757 people
- Sponsor
- University Medical Center Groningen
Alzheimer Disease, Depression
Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression
The global aim of our study is to validate eye movement recording as an early differential diagnostic tool, in order to discriminate as early as possible between neurodegenerative dementias of Alzheimer type and depressive…
- Trial name
- MOMAD (NCT01434940)
- Testing
- Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
- Where
- France
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.